Grant Award

Summary by AI BETAClose X

CRISM Therapeutics Corporation has been awarded a non-dilutive research and development grant of up to £99,902 from Invest Northern Ireland to advance its docetaxel-ChemoSeed programme for prostate cancer treatment. This funding, representing 61% of eligible project expenditure, will support key technical, preclinical, and regulatory activities through to March 2027, including manufacturing process optimization, analytical method validation, in vivo studies, and regulatory engagement planning. The company believes this award underscores the commercial potential of its ChemoSeed platform in the significant prostate cancer market, enabling critical development milestones while maintaining capital efficiency and enhancing the programme's value proposition.

Disclaimer*

UK 100

Latest directors dealings